NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,51.5179336238226,1.917344917105992,57.88516161218383,1.76256725015505,8.95647120560566,32.9356396294634,percent_activity,2,26.869413616817,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.80877116202939,1.80877116202939,0.585816096858276,20,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.11782248269454,1.2054921195950559,115.51308981389457,2.06263120078082,0.0927274815425616,1.09537473668145,log2_fold_induction,2.30102999566398,0.927274815425616,"[""Borderline active"",""Borderline active""]",2.15966492478942,1.99488832499337,1.92789159986658,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.41286222865106,1.5921738572008386,59.83254795551636,1.77693749756809,0.0887379366431112,1.33921192161267,log2_fold_induction,2.30102999566398,0.887379366431112,,1.92660416075795,1.35980618007726,1.14930484819824,20,cell cycle
APR_HepG2_MicrotubuleCSK_72h_up,"Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,1.54313557251489,1.486077038563116,87.06937067125799,1.93986540543358,0.103839540782283,1.28594631046629,log2_fold_induction,2.30102999566398,1.03839540782283,,2.14331252651827,1.55219157594802,1.32020037025735,20,cell morphology
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1, , , ,,,Active,1.3320440318495614,1.4544893611704712,10.586181173209873,1.0247393222881624,0.183163117917566,1.1100366932242942,log2_fold_induction,2,0.91581558958783,,1.5621987988889594,0.7837596830307119,-0.4727853589331341,20,dna binding
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3, , , ,,,Active,0.932086724109247,1.275884834321991,16.092270274369437,1.2066173180628788,0.14610828486013952,0.8329681789382516,log2_fold_induction,2,0.7305414243006976,"[""Borderline active""]",1.6679082574196769,1.163957164285485,0.4195525485138675,20,dna binding
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1", , , ,,,Active,1.816674242839322,3.0606811018076967,11.202148645180301,1.0493013311744697,0.11871045577184501,1.5138952023677124,log2_fold_induction,2,0.593552278859225,,0.5953710224398623,0.16329438417601805,-0.3301404367648597,20,nuclear receptor
ATG_E_Box_CIS_dn,ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_009053.1, , , ,,,Active,0.6810334887726738,1.4416827079521919,25.446690759972704,1.4056313120900998,0.09447758303767596,0.5675279073851358,log2_fold_induction,2,0.4723879151883798,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",2.5597532619639627,0.9275878839039822,-1.697621687438876,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,3.674647878787228,3.32501245791308,39.74509944945634,1.5992835880047644,0.22103062321117403,3.062206565682431,log2_fold_induction,2,1.10515311605587,,1.3812539545512759,1.208227510667347,1.0314921350470825,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.1296114211380854,2.2354796435480253,16.161425345551024,1.2084796604243229,0.10106210757931403,1.0807008145758499,log2_fold_induction,2,0.5053105378965701,,1.1579528269704675,0.968876186522162,0.6834669699566372,20,nuclear receptor
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2, , , ,,,Active,1.0650026866669187,1.7707781165539387,20.125704216928085,1.3037510856697248,0.12028640705584168,0.8875022393953921,log2_fold_induction,2,0.6014320352792084,"[""Hit-call potentially confounded by overfitting""]",1.4223339776155024,0.9992742841757408,0.30298862122671943,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2, , , ,"[61,61]",[478],Active,0.9557599270793528,1.2307160913256838,5.742888833834029,0.7591304096435687,0.15531769411576343,0.7964666059148613,log2_fold_induction,1.47712125471966,0.7765884705788172,"[""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.973510866399812,0.7518322822537414,0.43794365795983836,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3, , , ,,,Active,1.0542187205950242,1.555605864290257,10.897262819581822,1.037317425313691,0.13553802345377633,0.948567208402631,log2_fold_induction,2,0.6776901172688816,,1.2854319177563078,0.8408273916986775,0.1096896114321404,20,dna binding
ATG_PBREM_CIS_up,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1, , , ,"[8,107,58,8,107,58]","[456,715]",Active,0.5486606545573472,1.144428167214717,5.862328088978632,0.7680701203538196,0.09588380822409588,0.5512947879557507,log2_fold_induction,1.47712125471966,0.4794190411204794,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.8731136330265737,0.7733464533719484,0.6487898064620897,20,nuclear receptor
ATG_PPRE_CIS_up,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_005027.2|NP_006229.1|NP_056953.2", , , ,,,Active,1.1903035462165878,1.3293760995710602,31.84720881805695,1.5030713755085923,0.1790770191521653,0.9919196218961145,log2_fold_induction,2,0.8953850957608266,"[""Only highest conc above baseline, active"",""Borderline active""]",1.999916401022534,1.4157151563548356,0.5200673097818382,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,5.4608166089388535,8.194440677145126,5.676409281422123,0.7540737014885702,0.13328100901796647,4.550680507468485,log2_fold_induction,1.47712125471966,0.6664050450898323,,0.3191551934838418,0.19464347694212858,0.26980396531120204,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.2163993880456396,1.7207420344681124,14.987794712998237,1.1757377359548105,0.2576097222766731,2.2078453953481434,log2_fold_induction,2,1.2880486113833656,,1.230871069146507,1.0705439693507446,0.8058142707457459,20,nuclear receptor
ATG_RARa_TRANS_up,"Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000955.1, , , ,,,Active,3.059603255980941,2.6698044567270975,23.181999533142097,1.3651508927474287,0.22920055049512475,2.5496693799980275,log2_fold_induction,2,1.1460027524756238,,1.1383310871449104,0.8173396996008638,0.393105435003663,20,nuclear receptor
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,1.2721968210318602,1.7519139287540417,6.51952959616309,0.8142162611980756,0.1452350826317871,1.349179459390728,log2_fold_induction,2,0.7261754131589355,,0.8666247963435698,0.6943303080006579,0.41035857843094004,20,nuclear receptor
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.21599999999849345,2.727918677467854,39.99999999999999,1.6020599913279623,0.02172150128694,0.18,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.5457033264033712,20,cell cycle
BSK_BE3C_HLADR_down,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.09110737548746911,1.1506181076346176,39.99999999999999,1.6020599913279623,0.025097172292079997,0.089,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.8883991979717598,20,cell adhesion molecules
BSK_BE3C_IP10_down,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.12959996681588823,1.5483925990024754,39.99999999999999,1.6020599913279623,0.027899893713299997,0.108,log10_fold_induction,1.60205999132796,0.08369968113989999,"[""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.3953962087112735,20,cytokine
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.11759998280376067,1.4538983344333434,40.000000000000014,1.6020599913279625,0.0269619913164,0.098,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.3951971066129147,20,cytokine
BSK_LPS_TNFa_up,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2, , , ,,,Active,0.26999999994070445,1.9829366733960359,40.000000000000014,1.6020599913279625,0.04538722854225,0.225,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.416690768810699,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1, , , ,,,Active,0.133199999984234,1.2580391044697166,40.000000000000014,1.6020599913279625,0.03529302057225,0.111,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.6020599913279625,1.6020599913279625,0.5827063344937832,20,cytokine
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,119.661633888598,5.983081694429901,42.91302730163797,1.63258915293913,1.53481347591287,99.5957446805328,percent_activity,1.90308998699194,20,,1.35717796574613,1.08068451673454,1.25580089020801,20,malformation
CCTE_Shafer_MEA_acute_burst_duration_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_duration_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,70.40895011959941,2.135760630033562,36.2827489932971,1.5597001843249703,10.988895342404389,37.813416902030525,percent_activity,1.60205999132796,32.966686027213164,"[""Borderline active""]",1.4586621622447749,1.4586621622447749,-0.18420175757575552,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_number_up,"Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,136.9208464808907,2.737113711921773,25.69229372321388,1.4098028783756076,16.674602140753628,98.21108633251966,percent_activity,1.60205999132796,50.02380642226088,"[""Only one conc above baseline, active""]",1.1382995405376555,1.1382995405376555,0.32952969063231485,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,85.43734468460437,1.4578146887046177,1.3650487710380395,0.13514816831033605,19.53548356696422,86.86720297786759,percent_activity,1,58.606450700892665,,0.2246512823457017,0.2246512823457017,-0.116561496374889,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_area_up,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,229.38064303260342,4.582226073187273,13.08781887638564,1.1168672761247298,16.68625971808883,173.12191811870392,percent_activity,1.60205999132796,50.05877915426649,,0.38952683788085085,0.38952683788085085,-0.13560122412379094,20,neuroactivity
CCTE_Shafer_MEA_acute_firing_rate_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,212.83375071736688,4.062105539219237,19.749551313514097,1.2955572334167356,17.464977925239143,156.0223320411928,percent_activity,1.60205999132796,52.39493377571743,,0.8007611997644665,0.8007611997644665,0.3240843349224064,20,neuroactivity
CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,70.2452348186499,1.517847352388312,1.338904504957665,0.126749602815673,15.426504013094597,80.74483250633992,percent_activity,1.60205999132796,46.27951203928379,,0.1624743831906954,0.1624743831906954,0.007469287816972037,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,71.11965513694648,1.8097578694328933,1.123789216776863,0.050684860543385724,13.099294724848574,79.88523645590634,percent_activity,0.477121254719662,39.29788417454572,,0.062140465824870726,0.062140465824870726,-0.06859547856727669,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,71.10956024791388,3.446631763246176,1.23291965749757,0.09093477696693078,6.877203129753559,117.54075805236579,percent_activity,1.60205999132796,20.631609389260674,"[""Noisy data""]",0.04236369087688094,0.04236369087688094,-0.02834556098979793,20,neuroactivity
CCTE_Shafer_MEA_acute_spike_number_up,"Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,220.993455798234,4.204014106999743,20.545447353417714,1.3127156019622421,17.522416288619393,156.86445759103148,percent_activity,1.60205999132796,52.567248865858176,,0.7816248912669103,0.7816248912669103,0.3105504348304424,20,neuroactivity
CCTE_Shafer_MEA_acute_synchrony_index_up,"Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,77.69120316795127,1.5787617989106086,1.1272313829117544,0.052013071332379514,16.403404073065456,77.25539050595978,percent_activity,1,49.210212219196364,,0.08181966560777143,0.08181966560777143,-0.06774567517396551,20,neuroactivity
CCTE_Shafer_MEA_dev_interburst_interval_mean_up,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,102.757441891765,1.5894920442831422,13.467542843490094,1.1292883658153,21.5493249895668,70.0006247361771,percent_activity,1.47712125471966,64.6479749687004,"[""Only highest conc above baseline, active"",""Borderline active""]",1.38790760694773,1.38790760694773,0.0540737108374083,100,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_up,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,102.757441891765,1.5894920442831422,13.467542843490094,1.1292883658153,21.5493249895668,70.0006247361771,percent_activity,1.47712125471966,64.6479749687004,"[""Only highest conc above baseline, active"",""Borderline active""]",1.38790760694773,1.38790760694773,0.0540737108374083,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,81.6630561735849,1.043227745482112,0.5036126017717191,-0.297903411186403,26.0930739643514,80.2798425885439,percent activity,1.47712125471966,78.2792218930542,"[""Only highest conc above baseline, active"",""Borderline active""]",1.42789274041679,1.42789274041679,-1.50504524242708,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,81.6630561735849,1.043227745482112,0.5036126017717191,-0.297903411186403,26.0930739643514,80.2798425885439,percent activity,1.47712125471966,78.2792218930542,"[""Only highest conc above baseline, active"",""Borderline active""]",1.42789274041679,1.42789274041679,-1.50504524242708,100,neurodevelopment
CLD_CYP2B6_24hr,"Data from the assay component CLD_CYP2B6_24hr was analyzed at the endpoint, CLD_CYP2B6_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,4.94084534143091,4.94084534143091,1.6687632577521812,0.222394729043178,0.415288000995156,4.40378672890915,log2_fold_induction,1.60205999132796,1,,-0.616070883462727,-0.442282162853513,-1.12097965243481,20,cyp
CLD_CYP2B6_48hr,"Data from the assay component CLD_CYP2B6_48hr was analyzed at the endpoint, CLD_CYP2B6_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,3.3987438528829,3.3987438528829,0.09759055020712078,-1.01059223347668,0.450385337247368,2.90723540550804,log2_fold_induction,1.60205999132796,1,,-2.27720514943195,-1.61238238041716,-4.1914005981243,20,cyp
CLD_CYP2B6_6hr,"Data from the assay component CLD_CYP2B6_6hr was analyzed at the endpoint, CLD_CYP2B6_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,3.20440887463821,3.20440887463821,1.4298686112456809,0.155296132547192,0.396566308888419,3.00500556266639,log2_fold_induction,1.60205999132796,1,,-0.269492343562565,-0.127789802462605,-1.02548012615982,20,cyp
CLD_CYP3A4_24hr,"Data from the assay component CLD_CYP3A4_24hr was analyzed at the endpoint, CLD_CYP3A4_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,3.61793113937735,3.61793113937735,2.2879256674444726,0.359441910530473,0.719693813962598,3.69411849533713,log2_fold_induction,1.60205999132796,1,,0.196996422135279,0.425615321761754,-0.0114382001497967,20,cyp
CLD_CYP3A4_48hr,"Data from the assay component CLD_CYP3A4_48hr was analyzed at the endpoint, CLD_CYP3A4_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,4.50639220252709,4.50639220252709,0.5875872769320637,-0.230927616588418,0.783724870256564,3.49142655791943,log2_fold_induction,1.60205999132796,1,,-1.77769686052784,-0.123637353195747,-2.9398650177931,20,cyp
CLD_SULT2A_48hr,"Data from the assay component CLD_SULT2A_48hr was analyzed at the endpoint, CLD_SULT2A_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.",NP_003158.2, , , ,,,Active,1.59650677166197,1.59650677166197,1.8893394259761274,0.27630998734811,0.384258977273262,1.55775887441171,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.511626218418242,0.711136482924956,-0.724421475786178,20,transferase
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2, , , ,,,Active,1.0733967975753,2.829231805100609,7.802503256888863,0.892233958618827,0.126465046759354,0.836848747410505,log2_fold_induction,1.47712125471966,0.379395140278062,,0.584230757935732,0.584230757935732,-0.228409480443663,20,transporter
LTEA_HepaRG_ABCC2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000383.1, , , ,,,Active,0.700264237158118,1.6316914413769708,3.478306026705906,0.541367789243144,0.143054873284778,0.67596013892858,log2_fold_induction,1.47712125471966,0.429164619854334,,0.771652911465201,0.771652911465201,-0.560152775057417,20,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2, , , ,,,Active,1.06725163087191,1.7709744472651971,3.717257557633452,0.570222653101056,0.200878417062049,1.10353527136843,log2_fold_induction,2,0.602635251186147,,0.686369901677247,0.686369901677247,-0.410944366411541,20,transporter
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,2.99576025065431,3.3264762063452427,29.392416978413745,1.46823530016681,0.300193564683644,2.30616937210695,log2_fold_induction,2,0.900580694050932,,1.07856410882052,1.07856410882052,0.454212339465916,20,cyp
LTEA_HepaRG_CYP24A1_1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000773.2, , , ,,,Active,4.46626952610271,1.367011274695367,11.157572287747133,1.04756970923141,1.08905942201001,4.1085159723333,log2_fold_induction,2,3.26717826603003,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.5019666381415,1.5019666381415,0.051511007178036,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,2.21948511026507,2.944176159840612,0.37734715225981275,-0.423258923166994,0.251285361310856,2.371487545,log2_fold_induction,1,0.753856083932568,,-0.592633042976608,-0.592633042976608,-0.9830235578149,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1, , , ,,,Active,1.03856958682169,1.851904530565196,1.072004031569557,0.0301964186451091,0.186937207917646,1.06500031151658,log2_fold_induction,1.47712125471966,0.560811623752938,,0.0834566999496954,0.0834566999496954,-0.699927155065031,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,2.28140178784394,4.763564165906665,4.939916567232882,0.69371961396487,0.159642493756543,2.17961823774603,log2_fold_induction,2,0.478927481269629,,0.111332053592472,0.111332053592472,-0.271776596868775,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2, , , ,,,Active,2.05272471001934,1.7299491771703324,0.7605681302514775,-0.118861876591939,0.395526977922934,2.21371479921582,log2_fold_induction,1.47712125471966,1.1865809337688,,0.00941346655644351,0.00941346655644351,-1.01424724894078,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2, , , ,,,Active,2.46415625839188,3.85496418749724,12.02054432373521,1.07992413417605,0.213072127136213,1.98733548052721,log2_fold_induction,2,0.639216381408639,,0.414633524629318,0.414633524629318,-0.313507942941445,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2, , , ,,,Active,2.48783462309625,3.079989995124299,8.119296513193106,0.909518401941462,0.269247045935707,2.0527126119523,log2_fold_induction,2,0.807741137807121,,0.349333825224719,0.349333825224719,-0.771138839336542,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,1.23567585900579,2.3005516091093448,3.838719018999216,0.584186324421629,0.179040518530855,1.17714308116667,log2_fold_induction,2,0.537121555592565,,0.467570152655832,0.467570152655832,-0.390863684530534,20,cyp
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1, , , ,,,Active,1.23291376620459,2.5547635845820564,8.917032873110415,0.950220367694251,0.160864691309103,1.25684164891758,log2_fold_induction,2,0.482594073927309,,0.769662626080669,0.769662626080669,0.0512745628382195,20,transporter
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1, , , ,"[60,60]",,Active,1.78949550095558,3.418250618326038,48.07870468341057,1.68195275856987,0.174504027621778,1.17026753599108,log2_fold_induction,2,0.523512082865334,,1.18851483224709,1.18851483224709,0.454161781408482,20,lyase
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,1.41537025211919,2.9076136615104766,9.377000268856015,0.972063928460052,0.162260237763032,1.1848429822274,log2_fold_induction,2,0.486780713289096,"[""Noisy data"",""Noisy data""]",0.586516521128831,0.586516521128831,-0.339587714502035,20,growth factor
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1, , , ,,,Active,2.14417327321236,3.1552952298862507,26.805249615522037,1.42821985581199,0.226515863756396,1.62019054320188,log2_fold_induction,2,0.679547591269188,,1.00776233159525,1.00776233159525,0.225190466795419,20,dna binding
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1, , , ,,,Active,1.58638908462646,2.395140990716696,3.845166977548226,0.584915203917223,0.220778803248623,1.45076956399637,log2_fold_induction,2,0.662336409745869,,0.379767417478943,0.379767417478943,-0.768724070703756,20,transferase
NVS_MP_rPBR,"Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",NP_036647.1, , , ,,,Active,38.7863801781756,1.2348013691894444,17.838606656870184,1.25136092936384,5.23517130581576,38.7685750742126,percent_activity,1.69897000433602,31.4110278348946,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.33002343414307,1.23046091326706,1.13208048995824,20,transporter
NVS_TR_hDAT,"Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_001035.1, , , ,,,Active,100.95974160432,5.047987080216,6.6791493042127845,0.824721151695158,3.32006520794786,84.1331180066905,percent_activity,1.69897000433602,20,,-0.0155818215221755,-0.504802926229574,-0.495768247718564,20,transporter
OT_ER_ERbERb_0480,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,29.8077836698048,1.4903891834902399,38.36012172323129,1.58387997659153,3.03794948946985,24.8373101952278,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.75159151004907,1.39086901965508,1.06672774083689,20,nuclear receptor
OT_FXR_FXRSRC1_0480,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,36.7759792980445,1.4673035226096813,31.59905694191188,1.49967412150969,5.01272964064537,38.5204325772801,percent_activity,2,25.0636482032268,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.54097427044226,1.47967162410924,1.38039371891877,20,nuclear receptor
OT_NURR1_NURR1RXRa_0480,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_006177.1|NP_002948.1", , , ,,,Active,41.551916833932,2.057305303227825,93.80493520950488,1.97222568782333,4.03945070950227,23.9373443650092,percent_activity,2,20.1972535475113,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.96568956574254,1.86813584864699,1.7145009056425,20,nuclear receptor
TAMU_PeakParms_SingleDonor1434_Asystole,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Asystole was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Asystole, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is cessation of beating.",, , , ,,,Active,106.16897648343726,1.117568173509866,70.93543500981295,1.8508632363795174,9.724331715171544,100,percent_activity,2,95,"[""Borderline active"",""Only highest conc above baseline, active""]",1.9704434761000298,1.7966511608502793,1.7281276307043107,20,cardiomyocyte function
TAMU_PeakParms_SingleDonor1434_Chronotropy_Positive,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Chronotropy was analyzed into 2 assay endpoints. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Chronotropy_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is elevated beat rate.",, , , ,,,Active,38.84982208196146,7.769964416392293,17.574682330976586,1.244887483725956,8.715639461504102,32.29214660178016,percent_activity,2,5,"[""Only highest conc above baseline, active"",""Noisy data"",""Less than 50% efficacy""]",0.3389948942523736,1.5868304649755651,0.20412732627996366,20,cardiomyocyte function
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,31.1297417153481,1.556487085767405,37.71220099271982,1.57648187982271,2.57591984669775,29.4918751983,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.6570975055673,1.4240837741257,1.27426858047223,20,channel 1
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,26.8611265390494,1.2606098540556943,25.495467560941805,1.40646298089557,3.55134017774949,25.7019613935,percent_activity,1.90308998699194,21.3080410664969,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51982222728621,1.37109856787833,1.22123949835349,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1, , , ,,,Active,42.9629395473195,2.148146977365975,28.240546790584308,1.4508731012266,2.7369041511147,44.0403450259,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.43757419933495,1.31198201952066,1.23935794973143,20,dna binding
TOX21_AP1_BLA_Agonist_viability,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.",, , , ,,,Active,30.7559843724043,1.3632601167996818,68.47807781381323,1.83555156115259,3.76010222277627,23.4361616473,percent_activity,1.90308998699194,22.5606133366576,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.8905246307088,1.80590494876899,1.71627063051638,20,cell cycle
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,37.2353288800966,1.6147719069003432,35.19035179549993,1.54642360846863,3.8431979898606,37.8062813607,percent_activity,1.90308998699194,23.0591879391636,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.57283435744836,1.50289660597405,1.42714329182066,20,cell cycle
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,26.9839170129972,1.34919585064986,51.617323936100206,1.71279548509915,2.50978290890691,21.8550069104,percent_activity,1.95424250943932,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.88658166095578,1.55599757042665,1.34986501287982,20,dna binding
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2, , , ,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,45.118763930646,1.6812701748214016,43.84515068636695,1.64192156699255,4.47268624701549,43.994041235,percent_activity,1.95424250943932,26.8361174820929,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.67583098142822,1.56596150074585,1.44779099536505,20,cyp
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,59.7788104338919,2.4907196190821383,52.740702538561024,1.72214591056527,4.0001030208237,50.5944670047,percent_activity,1.95424250943932,24.0006181249422,,1.6775589327713,1.56785181304954,1.47677232851184,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,73.7428942169736,3.4188672620695475,34.50494410388571,1.53788132820938,3.59489896137582,67.1528718478,percent_activity,1.95424250943932,21.5693937682549,,1.33515596134025,1.13294834815876,1.03359797854701,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,58.0806710934767,2.216649005629653,27.247329255572954,1.4353239397719,4.36700254498032,57.1158367812,percent_activity,1.95424250943932,26.2020152698819,,1.41788401746627,1.32562237859484,1.239916724048,20,cell cycle
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3, , , ,,,Active,31.9199940096471,1.5105801026196581,80.24941461277787,1.90444187308479,3.52182515338437,21.3620031047,percent_activity,1.95424250943932,21.1309509203062,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.94093388744233,1.86624178058607,1.78516155893925,20,nuclear receptor
TOX21_ERR_viability,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,26.2659913995544,1.3132995699777201,77.15227967987043,1.88734876303379,2.25399102610353,20.6559348225,percent_activity,1.95424250943932,20,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.9503537885463,1.82984243034545,1.76806844867061,20,cell cycle
TOX21_H2AX_HTRF_CHO_viability,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,25.3432308475653,1.2671615423782652,104.716673319106,2.02001583692215,2.15763115046871,25.0094726598,percent_activity,2.30102999566398,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",2.09166920865087,1.96193059323569,1.90073533265615,20,cell cycle
TOX21_NFkB_BLA_agonist_ch1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,28.6848560155941,1.434242800779705,43.72909918454047,1.64077053101024,3.27484652838546,28.007671689,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.68605395363975,1.60536593421253,1.52149021465088,20,channel 1
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,42.52880767324,2.126440383662,66.21467124929876,1.82095422715383,2.8966141715805,35.4406737148,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.81106276613307,1.70801337128294,1.63841353870403,20,channel 1
TOX21_p53_BLA_p3_ch1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,22.4359282365974,1.0922540042432314,57.86952751230949,1.76244993649117,3.42349065166122,21.799008967,percent_activity,1.95424250943932,20.5409439099673,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.89182700582435,1.7532576705122,1.64316941764505,20,channel 1
TOX21_p53_BLA_p4_ch1,"Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,27.2870474454732,1.36435237227366,65.650413729458,1.81723746736159,2.74402988187153,25.2620591575,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.87204727875604,1.77167522021202,1.69795712846765,20,channel 1
TOX21_p53_BLA_p4_viability,"TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,39.2011526114111,1.6380081993535518,69.16727438310592,1.83990066213669,3.98870130064896,34.9484153723,percent_activity,1.95424250943932,23.9322078038938,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.86429742226615,1.79525366074988,1.72062013998012,20,cell cycle
TOX21_PGC_ERR_viability,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,28.4504258928651,1.4225212946432548,79.38196766048225,1.89972185966939,2.5904653717656,20.2211418611,percent_activity,1.95424250943932,20,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.94649078482532,1.84659297014701,1.78044154500607,20,cell cycle
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,46.0153088836427,2.3007654441821352,81.49339734006337,1.91112242328063,2.51198214229767,26.2509620943,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.85812972021105,1.58254152915478,1.46831737309804,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,70.7453103865456,3.53726551932728,66.40097109794814,1.82217443086495,1.80636679455099,48.440429142,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.5992378269374,1.2261049114399,1.2960777072494,20,nuclear receptor
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,39.8338803026851,1.5884769866650932,29.574682717763295,1.47092009413974,4.17946253309319,33.1949003592,percent_activity,1.90308998699194,25.0767751985591,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.6686486649751,1.18081587304367,0.651531617150125,20,cell cycle
TOX21_RT_HEK293_FLO_24hr_viability,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,63.5381586662439,2.3653263641329145,40.23679466522268,1.60462337675334,4.47705368342379,52.9484655611,percent_activity,1.90308998699194,26.8623221005427,,1.53585345733997,1.31386161397329,1.11937574086142,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,84.8297709363444,2.9838203714870497,40.464152514186715,1.60707044891079,4.73831980341741,70.6914757916,percent_activity,1.90308998699194,28.4299188205045,,1.4693853555909,1.28488978730026,1.16544378314511,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,32.3831958426901,1.1347398293931636,28.21587572370421,1.45049353382174,4.75633195144065,31.8205182796,percent_activity,1.90308998699194,28.5379917086439,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.55930653513318,1.43754031546202,1.33121321964755,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,37.0916776769168,1.5277395486289247,29.820430925292253,1.47451391500981,4.04646609105207,37.0059825403,percent_activity,1.90308998699194,24.2787965463124,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.50921147198584,1.43539976824401,1.35523355960843,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,33.943852438879,1.408093322144199,30.76545489637041,1.4880633409265,4.0177086637968,33.8837871212,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.53671845130142,1.45566825032082,1.36878291348518,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,27.8880385077538,1.1366558614168991,34.636713939849734,1.53953668284054,4.08919407864135,27.8418257088,percent_activity,1.90308998699194,24.5351644718481,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.64758315047416,1.5264198405797,1.42025636844685,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,30.3844430828989,1.209456280100578,32.998356871818046,1.51849231505156,4.18706647811088,25.3203692743,percent_activity,1.90308998699194,25.1223988686653,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",2.447878105533,1.31047341623719,0.212186836457134,20,cell cycle
TOX21_RT_HEPG2_FLO_08hr_viability,"TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,39.4316753146224,1.4016267947342267,65.43767906337212,1.81582788742602,4.68879869481702,32.8597305097,percent_activity,1.90308998699194,28.1327921689021,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.8653500525929,1.78382078670787,1.69654757356124,20,cell cycle
TOX21_RT_HEPG2_FLO_16hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,63.148693895994,2.284109887901928,54.340217797672004,1.73512137475426,4.60782660753093,52.6239119194,percent_activity,1.90308998699194,27.6469596451856,,1.70872482067035,1.60084398670684,1.50318577587729,20,cell cycle
TOX21_RT_HEPG2_FLO_24hr_viability,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,41.398559257719,1.5092416247196865,47.720242317336925,1.67870264029619,4.57167345723585,40.742189021,percent_activity,1.90308998699194,27.4300407434151,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.71534568242697,1.64056561982721,1.5593945565299,20,cell cycle
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,93.1910507892871,3.1826715414377507,53.807053653917244,1.73083921176628,4.88012714978376,77.6592093686,percent_activity,1.90308998699194,29.2807628987026,,1.64658585793974,1.54950250915633,1.49366845574372,20,cell cycle
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,78.5895068822161,2.9184426777336134,60.460194057653204,1.78146953678875,4.48809608184861,71.0294880418,percent_activity,1.90308998699194,26.9285764910917,,1.74609903344889,1.69589421585011,1.66218281557377,20,cell cycle
TOX21_RXR_BLA_Agonist_ratio,"Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.",NP_002948.1, , , ,,,Active,59.9930878205739,2.999654391028695,11.271778867819672,1.05199246010239,2.27839049691729,29.5993235867,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.852174619344092,0.460537023975732,0.418426926767313,20,dna binding
TOX21_SBE_BLA_Antagonist_ratio,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",NP_005891.1, , , ,,,Active,28.7986395315567,1.4115299992086008,37.0842366327903,1.56918934362612,3.40040470833105,28.7343623805,percent_activity,1.90308998699194,20.4024282499863,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.61738915806866,1.53658922213045,1.44990902533444,20,growth factor receptor
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,43.0161911509984,1.9172208630747265,81.17689145052235,1.90943241663225,3.73945711206963,28.8697644993,percent_activity,1.95424250943932,22.4367426724178,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.91412317913613,1.85287393789793,1.79015202460332,20,nuclear receptor
TOX21_TSHR_HTRF_Agonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,94.870759815971,3.4067642360877164,7.303903563568279,0.863555030396089,4.64129367543786,95.4763757507,percent_activity,1.95424250943932,27.8477620526272,,0.650682669474686,0.436932605365532,0.331006553167428,20,gpcr